39 peer-reviewed studies · Evidence score: 7.5/10
Xing SH et al. • Phytomedicine (2022)
Huperzine A significantly improved cognitive function scores in patients with Alzheimer's disease and vascular dementia.
Perng CH et al. • Psychopharmacology (2018)
The most effective intervention for dementia available is symptomatic treatment for vascular dementia.
Chan ES et al. • The Cochrane database of systematic reviews (2018)
We found moderate- to very low-quality evidence of benefit and harm of TCHMs for VaD.
Yang G et al. • PloS one (2013)
Huperzine A appears to have beneficial effects on improvement of cognitive function, daily living activity, and global clinical assessment in participants with Alzheimer's disease.
Azmal M et al. • Journal of computer-aided molecular design (2025)
The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Zhang ZJ et al. • Chemistry & biodiversity (2024)
This review is the first time covered the biological activity of the all LAs.
Wang BS et al. • Journal of Alzheimer's Disease (2020)
Huperzine A produced clinically meaningful cognitive improvements with a favorable risk-benefit profile.
Fan F et al. • Journal of Alzheimer's disease : JAD (2022)
Our study demonstrated that AChE inhibitors, Ginkgo biloba, and cerebrolysin are the optimum cognitive and activities of daily living medication for patients with AD.
Laver K et al. • BMJ open (2016)
Healthcare professionals should ensure that people with dementia are encouraged to exercise and that primary carers are trained and supported to provide safe and effective care for the person with dementia.
Hersant H et al. • CNS drugs (2023)
The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Degirmenci Y et al. • Medicina (Kaunas, Lithuania) (2023)
Finally, we aim to provide additional insights and propose new ideas for investigation that may be feasible and effective for the spectrum of PD-related cognitive impairment.
Villegas C et al. • IUBMB life (2022)
The purpose of this review is to expose the positive results of intervention with EGb 761® and Huperzine in patients with mild to moderate AD in the last 10 years, highlighting the pharmacological functions that justify their use in AD therapy.
Chauhan PS et al. • CNS & neurological disorders drug targets (2022)
This review discusses the therapeutical potential of several key nutrients that have been researched for treating AD treatment and the method of their neuroprotective intervention.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Friedli MJ et al. • Molecules (Basel, Switzerland) (2021)
Our goal is to provide an integrated overview of the molecular mechanisms through which HupA affects AD.
Cui CC et al. • Medicine (2019)
Evaluation of the clinically common anti-dementia drugs using NMA affirmed the utility of cholinesterase inhibitors, especially donepezil, in alleviating cognitive dysfunction of patients with AD.
Sanadgol N et al. • Current drug targets (2017)
Further studies with a focus on the molecular mechanisms of the protective natural compounds are needed to decrease possible side effects and to develop new medicines for MS.
Yue J et al. • The Cochrane database of systematic reviews (2012)
The currently available evidence is insufficient to assess the potential for huperzine A in the treatment of MCI.
Huang P et al. • Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica (2019)
Due to the low quality of original studies, more high-quality studies are needed to verify its efficacy.
Liang J et al. • Clinical interventions in aging (2018)
As the first NMA comparing the major drugs in market for AD, our study suggests that memantine might have a more significant benefit on cognition than other five drugs available.
Farooq MU et al. • CNS drugs (2017)
However, there is a need for more robust clinical trials focusing on executive function and other cognitive measures and incorporation of newer imaging modalities to provide additional evidence about the utility of these strategies in patients with VCI.